[Role of VEGF in diseases of the retina].
Angiogenesis is the process through which new blood vessels are formed, based on preexisting vessels, and is the paradigm of diseases such as cancer and exudative ageassociated macular degeneration (ARMD). Several proangiogenic factors have been identified, such as vascular endothelial growth factor (VEGF), especially VEGF-A, which activates endothelial cells and promotes cell proliferation, migration, and an increase in vascular permeability. VEGF is also involved in the etiopathogenesis of other retinal diseases, such as diabetic macular edema and macular edema secondary to retinal vein occlusion. Likewise, there is increasing evidence that placental growth factor (PIGF) acts recepsynergetically with VEGF in promoting these diseases. Currently, the main treatment for these diseases are the anti-VEGF drugs, aflibercept, ranibizumab and bevacizumab. These agents differ in their molecular structure and mechanism of action.
Jefe de Sección de Retina y Vítreo, del Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España; Profesor Asociado de la Universidad de Barcelona, Barcelona, España; Sociedad Española de la Retina y Vítreo, Instituto de Salud Carlos III, Madrid, España; Red Temática de Investigación Cooperativa OFTARED, Instituto de Salud Carlos III, Madrid, España. Electronic address: luisarias@telefonica.net.
Luis Arias
LA
Barquet
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000068258:Bevacizumab / Q000494:pharmacology / Q000627:therapeutic use; D002199:Capillary Permeability / Q000502:physiology; D003930:Diabetic Retinopathy / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D042783:Endothelial Cells / Q000187:drug effects / Q000473:pathology; D005136:Eye Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000494:pharmacology / Q000627:therapeutic use; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D008565:Membrane Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D000069579:Ranibizumab / Q000494:pharmacology / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use; D015861:Retinal Neovascularization / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D012170:Retinal Vein Occlusion / Q000150:complications; D012171:Retinal Vessels / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000502:physiology*; D042561:Vascular Endothelial Growth Factor B / Q000037:antagonists & inhibitors / Q000502:physiology
D020533:Angiogenesis Inhibitors; D005136:Eye Proteins; D007141:Immunoglobulin Fc Fragments; D008565:Membrane Proteins; C098069:PIGF protein, human; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; C467485:VEGFB protein, human; D042461:Vascular Endothelial Growth Factor A; D042561:Vascular Endothelial Growth Factor B; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab
Angiogenesis; Angiogénesis; Degeneración macular asociada a la edad exudativa; Diabetic macular edema; Edema macular diabético; Edema macular secundario a oclusiones venosas retinianas; Exudative age-related macular degeneration (ARMD); Factor de crecimiento del endotelio vascular; Factor de crecimiento placentario; Placental Growth Factor (PIGF); Terapia antifactor de crecimiento del endotelio vascular; Vascular Endothelial Growth Factor (VEGF)